Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.
Revenue (Most Recent Fiscal Year) | $124.46M |
Net Income (Most Recent Fiscal Year) | $-66.07M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 12.04 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.96 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -52.65% |
Net Margin (Trailing 12 Months) | -53.08% |
Return on Equity (Trailing 12 Months) | -43.57% |
Return on Assets (Trailing 12 Months) | -26.03% |
Current Ratio (Most Recent Fiscal Quarter) | 4.88 |
Quick Ratio (Most Recent Fiscal Quarter) | 4.64 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.30 |
Inventory Turnover (Trailing 12 Months) | 2.13 |
Book Value per Share (Most Recent Fiscal Quarter) | $0.72 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
Earnings per Share (Most Recent Fiscal Year) | $-0.30 |
Diluted Earnings per Share (Trailing 12 Months) | $-0.30 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 232.69M |
Free Float | 219.89M |
Market Capitalization | $1.50B |
Average Volume (Last 20 Days) | 4.83M |
Beta (Past 60 Months) | 0.85 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 5.50% |
Percentage Held By Institutions (Latest 13F Reports) | 58.92% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |